S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:GHRS

GH Research (GHRS) Stock Forecast, Price & News

$11.98
+0.33 (+2.83%)
(As of 06/2/2023 ET)
Compare
Today's Range
$11.73
$12.24
50-Day Range
$7.49
$11.98
52-Week Range
$5.70
$17.41
Volume
13,318 shs
Average Volume
67,538 shs
Market Capitalization
$605.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.25

GH Research MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
302.8% Upside
$48.25 Price Target
Short Interest
Bearish
4.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of GH Research in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.07) to ($1.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

581st out of 983 stocks

Pharmaceutical Preparations Industry

289th out of 486 stocks


GHRS stock logo

About GH Research (NASDAQ:GHRS) Stock

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

GHRS Stock News Headlines

GH Research (NASDAQ:GHRS) Trading Down 5.8%
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
GH Research: Q1 Earnings Insights
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Unilever Ghana Ltd
GH Research (GHRS) Investor Presentation - Slideshow
Massachusetts General Hospital
GHRS.OQ - | Stock Price & Latest News | Reuters
See More Headlines

GHRS Price History

GHRS Company Calendar

Last Earnings
5/11/2023
Today
6/02/2023
Next Earnings (Estimated)
8/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GHRS
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.25
High Stock Price Forecast
$66.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+302.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-22,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.79 per share

Miscellaneous

Free Float
29,504,000
Market Cap
$605.23 million
Optionable
Not Optionable
Beta
0.73

Key Executives

  • Mr. Florian Schonharting M.Sc. (Econ) (Age 53)
    Co-Founder & Non-Exec. Chairman
  • Mr. Theis Terwey M.D. (Age 45)
    Co-Founder & CEO
  • Mr. Magnus Halle (Age 24)
    Co-Founder & MD of Ireland
  • Ms. Julie Ryan A.C.A. (Age 36)
    VP of Fin.













GHRS Stock - Frequently Asked Questions

Should I buy or sell GH Research stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GHRS shares.
View GHRS analyst ratings
or view top-rated stocks.

What is GH Research's stock price forecast for 2023?

4 equities research analysts have issued 12-month price targets for GH Research's shares. Their GHRS share price forecasts range from $33.00 to $66.00. On average, they anticipate the company's stock price to reach $48.25 in the next year. This suggests a possible upside of 302.8% from the stock's current price.
View analysts price targets for GHRS
or view top-rated stocks among Wall Street analysts.

How have GHRS shares performed in 2023?

GH Research's stock was trading at $9.72 at the beginning of the year. Since then, GHRS shares have increased by 23.3% and is now trading at $11.98.
View the best growth stocks for 2023 here
.

Are investors shorting GH Research?

GH Research saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,280,000 shares, an increase of 5.8% from the April 30th total of 1,210,000 shares. Based on an average trading volume of 68,900 shares, the short-interest ratio is currently 18.6 days. Approximately 5.0% of the company's shares are short sold.
View GH Research's Short Interest
.

When is GH Research's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 22nd 2023.
View our GHRS earnings forecast
.

How were GH Research's earnings last quarter?

GH Research PLC (NASDAQ:GHRS) announced its earnings results on Thursday, May, 11th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03.

What ETFs hold GH Research's stock?

ETFs with the largest weight of GH Research (NASDAQ:GHRS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).iShares MSCI Ireland ETF (EIRL).

When did GH Research IPO?

(GHRS) raised $150 million in an IPO on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

What is GH Research's stock symbol?

GH Research trades on the NASDAQ under the ticker symbol "GHRS."

Who are GH Research's major shareholders?

GH Research's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (8.46%), Mirae Asset Global Investments Co. Ltd. (0.19%), Geode Capital Management LLC (0.10%), AdvisorShares Investments LLC (0.09%), PEAK6 Investments LLC (0.04%) and Renaissance Technologies LLC (0.02%).

How do I buy shares of GH Research?

Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GH Research's stock price today?

One share of GHRS stock can currently be purchased for approximately $11.98.

How much money does GH Research make?

GH Research (NASDAQ:GHRS) has a market capitalization of $605.23 million. The company earns $-22,460,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.

How can I contact GH Research?

The official website for the company is www.ghres.com. The company can be reached via phone at 212-450-4000 or via email at investors@ghres.com.

This page (NASDAQ:GHRS) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -